DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong ...

Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...

Shares of DexCom Inc. DXCM shed 9.30% to $61.80 Thursday, on what proved to be an all-around grim trading session for the ...

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

DexCom Inc. closed 52.01% short of its 52-week high of $141.99, which the company achieved on April 9th.

SAN DIEGO, April 03, 2025--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025. Management will ...

DexCom (DXCM) announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for ...

$DXCM insiders have traded $DXCM stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales. We have seen ...

DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost ...

In its fourth quarter 2024 investor letter, Sands Capital Select Growth Fund emphasized stocks such as DexCom, Inc. (NASDAQ:DXCM). DexCom, Inc. (NASDAQ:DXCM) is a medical device company that ...